Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

Masaki Yoshida1, Junzo Kudoh2, Yukio Homma3, Kazuki Kawabe41Department of Medical Informatics, 2Department of Urology, Japan Labor Health and Welfare Organization, Kumamoto Rosai Hospital, Kumamoto, Japan; 3Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 4T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshida M, Kudoh J, Homma Y, Kawabe K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	α1A-adrenoceptor-selective antagonist silodosin BPH LUTS Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/24526439b03a4c61be4e492429fa8b6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:24526439b03a4c61be4e492429fa8b6e
record_format	dspace
spelling	oai:doaj.org-article:24526439b03a4c61be4e492429fa8b6e2021-12-02T01:09:32ZSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasia1178-1998https://doaj.org/article/24526439b03a4c61be4e492429fa8b6e2011-06-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-silodosin-for-the-treatment-of-benign-prostatic-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Masaki Yoshida1, Junzo Kudoh2, Yukio Homma3, Kazuki Kawabe41Department of Medical Informatics, 2Department of Urology, Japan Labor Health and Welfare Organization, Kumamoto Rosai Hospital, Kumamoto, Japan; 3Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 4Tokyo Teishin Hospital, Tokyo, JapanAbstract: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the α1-adrenergic receptor antagonists. Silodosin is a new α1-adrenergic receptor antagonist that is selective for the α1A-adrenergic receptor. By antagonizing α1A-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor, it minimizes the propensity for blood pressure-related adverse effects caused by α1B-adrenergic receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 8 mg exhibited significant improvements in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving placebo. Silodosin showed early onset of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel selective α1A-adrenergic receptor antagonist, was effective in general and without obtrusive side effects. This review provides clear evidence in support of the clinical usefulness of silodosin in the treatment of LUTS associated with BPH.Keywords: α1A-adrenoceptor antagonist, silodosin, selective, benign prostatic hyperplasia, lower urinary tract symptomsYoshida MKudoh JHomma YKawabe KDove Medical Pressarticleα1A-adrenoceptor-selective antagonistsilodosinBPHLUTSGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 161-172 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	α1A-adrenoceptor-selective antagonist silodosin BPH LUTS Geriatrics RC952-954.6
spellingShingle	α1A-adrenoceptor-selective antagonist silodosin BPH LUTS Geriatrics RC952-954.6 Yoshida M Kudoh J Homma Y Kawabe K Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
description	Masaki Yoshida1, Junzo Kudoh2, Yukio Homma3, Kazuki Kawabe41Department of Medical Informatics, 2Department of Urology, Japan Labor Health and Welfare Organization, Kumamoto Rosai Hospital, Kumamoto, Japan; 3Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 4Tokyo Teishin Hospital, Tokyo, JapanAbstract: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the α1-adrenergic receptor antagonists. Silodosin is a new α1-adrenergic receptor antagonist that is selective for the α1A-adrenergic receptor. By antagonizing α1A-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor, it minimizes the propensity for blood pressure-related adverse effects caused by α1B-adrenergic receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 8 mg exhibited significant improvements in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving placebo. Silodosin showed early onset of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel selective α1A-adrenergic receptor antagonist, was effective in general and without obtrusive side effects. This review provides clear evidence in support of the clinical usefulness of silodosin in the treatment of LUTS associated with BPH.Keywords: α1A-adrenoceptor antagonist, silodosin, selective, benign prostatic hyperplasia, lower urinary tract symptoms
format	article
author	Yoshida M Kudoh J Homma Y Kawabe K
author_facet	Yoshida M Kudoh J Homma Y Kawabe K
author_sort	Yoshida M
title	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
title_short	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
title_full	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
title_fullStr	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
title_full_unstemmed	Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
title_sort	safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/24526439b03a4c61be4e492429fa8b6e
work_keys_str_mv	AT yoshidam safetyandefficacyofsilodosinforthetreatmentofbenignprostatichyperplasia AT kudohj safetyandefficacyofsilodosinforthetreatmentofbenignprostatichyperplasia AT hommay safetyandefficacyofsilodosinforthetreatmentofbenignprostatichyperplasia AT kawabek safetyandefficacyofsilodosinforthetreatmentofbenignprostatichyperplasia
_version_	1718403243055251456

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

Ejemplares similares